Pfizer Inc (PFE.N)

PFE.N on New York Stock Exchange

34.84USD
12:00pm EDT
Change (% chg)

$0.40 (+1.16%)
Prev Close
$34.44
Open
$34.43
Day's High
$34.84
Day's Low
$34.43
Volume
2,008,169
Avg. Vol
7,274,519
52-wk High
$35.53
52-wk Low
$27.51

PFE.N

Chart for PFE.N

About

Pfizer Inc. is a bio pharmaceutical company. The company applies science and resources to discover, develop and manufacture healthcare products. The Company provides medicines, vaccines and consumer healthcare products. The Company operates its business through three operating segments, which include Global Innovative Pharmaceut... (more)

Overall

Beta: 0.75
Market Cap(Mil.): $212,070.20
Shares Outstanding(Mil.): 6,157.67
Dividend: 0.28
Yield (%): 3.25

Financials

  PFE.N Industry Sector
P/E (TTM): 23.82 36.11 38.09
EPS (TTM): 1.45 -- --
ROI: 6.44 16.12 15.45
ROE: 12.69 16.91 16.49
Search Stocks

Deals of the day- Mergers and acquisitions

May 29 - The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Friday:

9:34am EDT

French biotech firm Cellectis jumps on takeover hopes

- Shares in French cancer drugmaker Cellectis hit an all-time high on Friday on hopes it would be the latest in a string of bid targets in the healthcare sector, after reported interest from companies including Pfizer .

5:15am EDT

UPDATE 2-French biotech firm Cellectis jumps on takeover hopes

May 29 - Shares in French cancer drugmaker Cellectis hit an all-time high on Friday on hopes it would be the latest in a string of bid targets in the healthcare sector, after reported interest from companies including Pfizer .

5:13am EDT

French drugmaker Cellectis in sale talks: FT

- French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc , the Financial Times reported citing people familiar with the matter.

28 May 2015

French drugmaker Cellectis in sale talks -FT

May 28 - French cancer drugmaker Cellectis is in potential sale talks with a few suitors, including U.S. based Pfizer Inc, the Financial Times reported citing people familiar with the matter.

28 May 2015

UPDATE 1-FDA approves Pfizer drug to treat very rare lung disease

WASHINGTON, May 28 - The U.S. Food and Drug Administration on Thursday approved the first drug to treat a rare, progressive lung disease that mainly affects women of childbearing age.

28 May 2015

Roche drug shrinks tumors in half of patients with lung cancer mutation

- A drug being developed by Roche Holding AG was shown in pivotal trials to shrink tumors in patients with advanced lung cancer with a specific gene mutation who had stopped responding to crizotinib, another drug in the same class.

13 May 2015

Business groups say ADA doesn't entitle blind Pfizer worker to driver

- Three major business groups have asked a U.S. appeals court to uphold the dismissal of a former Pfizer Inc sales representative's suit claiming the pharmaceutical giant violated federal law by refusing to provide her with a full-time driver when she became legally blind.

13 May 2015

Mylan chairman said to consider Perrigo sweeteners to make deal: Bloomberg

- Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc by adding terms that will reduce risk to Perrigo's shareholders, sources told Bloomberg on Monday.

11 May 2015

Mylan chairman said to consider Perrigo sweeteners to make deal -Bloomberg

May 11 - Mylan NV's Chairman Robert Coury said he may sweeten the company's offer for Perrigo Co Plc by adding terms that will reduce risk to Perrigo's shareholders, sources told Bloomberg on Monday.

11 May 2015

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $100.94 -0.21
Novartis AG (NOVN.VX) CHF96.50 -1.95
Merck & Co., Inc. (MRK.N) $59.79 +0.09
Roche Holding Ltd. (ROG.VX) CHF276.20 -6.30
Abbott Laboratories (ABT.N) $48.67 -0.59
Bayer AG (BAYGn.DE) €129.15 -4.25
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €89.15 -3.12
AstraZeneca plc (AZN.L) 4,372.50p -119.50
GlaxoSmithKline plc (GSK.L) 1,453.50p -6.50

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: MarketLine (a Datamonitor Company)
$175.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks